Abstract
It is often suggested that one reason that neuroprotection trials in head injury have not shown benefit is the insensitivity of the outcome measures employed. The review considers strengths and weaknesses of the main approaches to assessing outcome in head injury trials. Determination of a response to neuroprotection requires a measure that is both sensitive to differences in outcome and is also influenced by brain injury. Sets of tests have been proposed for use in clinical trials that include scales of disability and handicap and measures of neuropsychological impairment. The Glasgow Outcome Scale (GOS) covers the whole spectrum of outcome after head injury and is the most popular primary endpoint for head injury trials. Although the GOS is a simple scale, small changes in the distribution of outcome can be detected with appropriate sample sizes. Late outcome in survivors can be influenced by various personal and environmental factors in addition to initial brain pathology. Other rating scales and questionnaires do not appear to offer significant advantages over the GOS, but can be used to supplement the information collected. Neuropsychological tests have properties that make them attractive as outcome measures, although there are practical difficulties with using tests. Neuropsychological assessment is potentially a powerful way of testing specific hypotheses concerning the effects of treatment. All current outcome measures have limitations choice of the most appropriate endpoint will depend both on the properties of the measures available, and on the anticipated effects of treatment.
Keywords: Head injury, Glasgow outcome scale GOS
Current Pharmaceutical Design
Title: Assessing Outcome in Head Injury Trials
Volume: 7 Issue: 15
Author(s): J. T.Lindsay Wilson
Affiliation:
Keywords: Head injury, Glasgow outcome scale GOS
Abstract: It is often suggested that one reason that neuroprotection trials in head injury have not shown benefit is the insensitivity of the outcome measures employed. The review considers strengths and weaknesses of the main approaches to assessing outcome in head injury trials. Determination of a response to neuroprotection requires a measure that is both sensitive to differences in outcome and is also influenced by brain injury. Sets of tests have been proposed for use in clinical trials that include scales of disability and handicap and measures of neuropsychological impairment. The Glasgow Outcome Scale (GOS) covers the whole spectrum of outcome after head injury and is the most popular primary endpoint for head injury trials. Although the GOS is a simple scale, small changes in the distribution of outcome can be detected with appropriate sample sizes. Late outcome in survivors can be influenced by various personal and environmental factors in addition to initial brain pathology. Other rating scales and questionnaires do not appear to offer significant advantages over the GOS, but can be used to supplement the information collected. Neuropsychological tests have properties that make them attractive as outcome measures, although there are practical difficulties with using tests. Neuropsychological assessment is potentially a powerful way of testing specific hypotheses concerning the effects of treatment. All current outcome measures have limitations choice of the most appropriate endpoint will depend both on the properties of the measures available, and on the anticipated effects of treatment.
Export Options
About this article
Cite this article as:
Wilson T.Lindsay J., Assessing Outcome in Head Injury Trials, Current Pharmaceutical Design 2001; 7 (15) . https://dx.doi.org/10.2174/1381612013397276
DOI https://dx.doi.org/10.2174/1381612013397276 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modulation of Cellular Function by TAT Mediated Transduction of Full Length Proteins
Current Protein & Peptide Science Autonomic Nervous System in Viral Myocarditis: Pathophysiology and Therapy
Current Pharmaceutical Design GCPII Imaging and Cancer
Current Medicinal Chemistry Radiological Diagnosis of Renal Thrombosis in Children
Current Pediatric Reviews Studies on the Pathophysiology and Genetic Basis of Migraine
Current Genomics Withdrawal Notice: Evaluation of Clinical Profile, Diagnostic Tests, And Prognosis of Crypto-coccal Meningitis in HIV Infected Patients in Western India
Infectious Disorders - Drug Targets Surgical Treatment of Pulmonary Embolism and Chronic Thromboembolic Pulmonary Hypertension
Current Pharmaceutical Design Cardiovascular Pharmacogenetics of Anti-Thrombotic Agents and Non-Steroidal Anti-Inflammatory Drugs
Current Molecular Medicine Role of Free Radicals and Poly(ADP-Ribose)Polymerase-1 in the Development of Spinal Cord Injury: New Potential Therapeutic Targets
Current Medicinal Chemistry New Perspectives in Glioma Immunotherapy
Current Pharmaceutical Design Prothymosin α and its C-Terminal Immunoreactive Decapeptide Show No Evidence of Acute Toxicity: A Preliminary <i>In Silico</i>, <i>In Vitro</i> and <i>In Vivo</i> Investigation
Current Medicinal Chemistry P2Y Receptors: Focus on Structural, Pharmacological and Functional Aspects in the Brain
Current Medicinal Chemistry Computational Models of Neuronal Biophysics and the Characterization of Potential Neuropharmacological Targets
Current Medicinal Chemistry Engineered Probiotic and Prebiotic Nutraceutical Supplementations in Combating Non-communicable Disorders: A Review
Current Pharmaceutical Biotechnology Near-Infrared Spectroscopy (NIRS): A Non-Invasive In Vivo Methodology for Analysis of Brain Vascular and Metabolic Activities in Real Time in Rodents
Current Vascular Pharmacology Noscapine and its Analogs as Chemotherapeutic Agent: Current updates
Current Topics in Medicinal Chemistry Gene Therapy for Ocular Neovascularization
Current Gene Therapy Microdialysis in Drug Discovery
Current Drug Discovery Technologies Small Molecule Tyrosine Kinase Inhibitors: Potential Role in Pediatric Malignant Solid Tumors
Current Cancer Drug Targets Peptide Aptamers: Development and Applications
Current Topics in Medicinal Chemistry